한글목차

모르그라모스팀 네뷸라이저액(모르그라모스팀)은 유전자 재조합 인간 과립구 대식세포 콜로니 자극 인자(GM-CSF)의 비글리코실화 제제입니다. 모르그라모스팀의 흡입에 의해 폐포의 대식세포가 활성화되기 때문에 폐포 대식세포의 서팩턴트 제거 활성이 회복되어 산소화가 대폭 개선될 가능성이 있습니다.

향후 수년간 자가면역성 폐포단백증(aPAP) 시장 시나리오는 세계의 광범위한 조사와 의료 지출 증가에 따라 변화할 것으로 예상됩니다.의 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 모르 그라 모스 팀 우위에 영향을 줄 수있는 기회를 모색하고 있습니다.자가 면역 폐포 단백질(aPAP)에 대한 다른 신흥 제품은 모르 그라 모스 팀과의 엄격한 시장 경쟁이 될 것으로 예상되며 가까운 미래에 후발 신흥 치료제가 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

본 보고서는 주요 7개국의 모르그라모스팀 시장에 대해 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장자가면역성 폐포단백증(aPAP)에서의 모르그라모스팀의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 모르그라모스팀 시장 평가

• 자가면역성 폐포단백증(aPAP)에서의 모르그라모스팀 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"Molgramostim Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the seven major markets. A detailed picture of the Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP). The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Molgramostim market forecast analysis for Autoimmune pulmonary alveolar proteinosis (aPAP) in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Autoimmune pulmonary alveolar proteinosis (aPAP).

Drug Summary:

Molgramostim nebulizer solution (molgramostim) is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara is developing an inhaled formulation as a potential treatment option for autoimmune pulmonary alveolar proteinosis (aPAP). The inhalation of molgramostim activates macrophages in the lung alveoli, thus potentially restoring the surfactant-clearing activity of the alveolar macrophages and considerably improving oxygenation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Molgramostim description, mechanism of action, dosage and administration, research and development activities in Autoimmune pulmonary alveolar proteinosis (aPAP).
• Elaborated details on Molgramostim regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Molgramostim research and development activities in Autoimmune pulmonary alveolar proteinosis (aPAP) across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Molgramostim.
• The report contains forecasted sales of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for autoimmune pulmonary alveolar proteinosis (aPAP).
• The report also features the SWOT analysis with analyst views for Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Molgramostim Analytical Perspective by DelveInsight

• In-depth Molgramostim Market Assessment

This report provides a detailed market assessment of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Molgramostim Clinical Assessment

The report provides the clinical trials information of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Autoimmune pulmonary alveolar proteinosis (aPAP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Molgramostim dominance.
• Other emerging products for Autoimmune pulmonary alveolar proteinosis (aPAP) are expected to give tough market competition to Molgramostim and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).
• Our in-depth analysis of the forecasted sales data of Molgramostim from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).

Key Questions:

• What is the product type, route of administration and mechanism of action of Molgramostim?
• What is the clinical trial status of the study related to Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Molgramostim development?
• What are the key designations that have been granted to Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• What is the forecasted market scenario of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• What are the forecasted sales of Molgramostim in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• Which are the late-stage emerging therapies under development for the treatment of Autoimmune pulmonary alveolar proteinosis (aPAP)?

Table of Contents

1. Report Introduction

2. Molgramostim Overview in Autoimmune pulmonary alveolar proteinosis (aPAP)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Molgramostim Market Assessment

• 5.1. Market Outlook of Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Molgramostim in the 7MM for Autoimmune pulmonary alveolar proteinosis (aPAP)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Molgramostim in the United States for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.2. Market Size of Molgramostim in Germany for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.3. Market Size of Molgramostim in France for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.4. Market Size of Molgramostim in Italy for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.5. Market Size of Molgramostim in Spain for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.6. Market Size of Molgramostim in the United Kingdom for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.7. Market Size of Molgramostim in Japan for Autoimmune pulmonary alveolar proteinosis (aPAP)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options